Clinical trial · Interventional
Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas
The Role of the 595 nm Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas at Low Risk Anatomical Sites: Outcome of a Double Blind Randomized Placebo Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pulsed dye laser (PDL) treatments have been suggested to be a safe and effective therapeutic approach for treating basal cell carcinomas. Robust supporting evidence is, however, lacking due to inconsistent design of available studies. The purpose of this study is to evaluate the PDL's efficacy and safety in treating superficial basal cell carcinoma (sBCC) at low risk anatomical sites in an evidence based study setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laser treatment | Procedure | — | UNRESOLVED |
| SHAM-Treatment | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Laser Treatment
- description
- Pulsed dye laser 595nm
- interventionNames
- Procedure: Laser treatment
- type
- SHAM_COMPARATOR
- label
- SHAM Treatment
- description
- using the pulsed dye laser (PDL) laser without releasing a pulse
- interventionNames
- Device: SHAM-Treatment
Primary outcomes (1)
- measure
- complete response
- timeFrame
- 9 months
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed unpigmented sBCC on the trunk and extremities * maximal tumour diameter 30 mm Exclusion Criteria: * Fitzpatrick skin type \>III * pregnancy * previous BCC treatment within 4 weeks * coagulation disorders * photo sensitizing medication * any indication of poor compliance
References
Publications (0)
Data not yet available